Subscribe: WSJ.com: Health
http://www.wsj.com/xml/rss/3_7089.xml
Preview: WSJ.com: Health

WSJ.com: Health



Health



Last Build Date: Mon, 20 Feb 2017 00:30:16 EST

Copyright: copyright © 2017 Dow Jones & Company, Inc.
 



Antitrust Rulings Put Chill on Health-Insurance Mergers

Wed, 15 Feb 2017 09:47:10 EST

Cigna called off the roughly $48 billion merger with Anthem and filed a lawsuit against its suitor, the second such health-insurer deal to fall apart.



Merck Stops Clinical Trial of Alzheimer's Drug

Tue, 14 Feb 2017 18:37:01 EST

Merck & Co. said Tuesday it stopped a clinical trial of an experimental Alzheimer’s drug because it wasn’t helping patients.



Door Opens to Gene Editing in Embryos

Tue, 14 Feb 2017 22:08:05 EST

The nonprofit National Academies of Sciences and the National Academy of Medicine commissioned a study of the ethical, scientific and regulatory questions raised by editing genes in sperm, eggs and early-stage embryos.



The Rise and Fall of a K Street Renegade

Mon, 13 Feb 2017 18:05:35 EST

Evan Morris, a high-flying corporate lobbyist, is suspected by federal prosecutors of embezzling millions of dollars from his employers, Roche and then Genentech. The probe is shaping up to be one of the biggest Washington influence scandals in years.



Teva Swings to Loss, But Beats Expectations

Mon, 13 Feb 2017 23:05:01 EST

Teva Pharmaceuticals swung to a loss on an acquisition write-down, as its interim CEO contends with a deal-driven debt load, though shares rose as the company beat revenue and profit expectations.



Firm Delays Muscular Dystrophy Drug Launch Amid Criticism of $89,000 Price

Tue, 14 Feb 2017 10:01:14 EST

Marathon Pharmaceuticals will delay the U.S. launch of its muscular dystrophy drug amid mounting criticism of its $89,000-a-year price, including from two members of Congress who launched an investigation Monday.



Allergan to Buy Fat-Treatment Maker Zeltiq for $2.3 Billion

Mon, 13 Feb 2017 17:46:54 EST

Allergan PLC said it would buy Zeltiq Aesthetics Inc., the maker of a fat-reducing treatment, for $2.26 billion.



No Drugs for Back Pain, New Guidelines Say

Tue, 14 Feb 2017 00:37:45 EST

The American College of Physicians says back pain of all kinds should be treated with natural and alternative therapies, such as exercise, acupuncture and mindfulness.



Hospitals Weigh Difficult Choice Amid Travel-Ban Uncertainty

Sun, 12 Feb 2017 20:24:18 EST

Hospital officials say President Donald Trump’s executive order leaves them with a difficult choice: forgo strong residency candidates from countries named in the order or risk vacancies if foreign doctors are barred from the U.S.



70-Fold Price Increase Puts Drug at $89,000

Sat, 11 Feb 2017 00:09:51 EST

Marathon Pharmaceuticals will charge $89,000 annually in the U.S. for a decades-old steroidal drug that was approved for U.S. sale for the first time on Thursday, a price that is as much as 70 times higher than the drug’s price overseas.



Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion

Fri, 10 Feb 2017 17:14:42 EST

Reckitt Benckiser said it agreed to buy baby-food maker Mead Johnson for $16.6 billion, a cash deal that will almost double the size of the British company’s consumer-health business and help it push deeper into emerging markets.



As HHS Head, Price Has Wide Latitude to Shape Obamacare's Fate

Fri, 10 Feb 2017 16:47:52 EST

The Georgia Republican was approved in a party-line vote Friday morning, placing him atop a sprawling agency tasked with dismantling the Affordable Care Act.